Valbiotis announces the first scientific publication of the bioavailability and mode of action clinical study on TOTUM•070 against hypercholesterolemia in the special issue “Foods, Plant Bioactives and Nutraceuticals for Reducing Cardiometabolic Disease Risk” from the peer-reviewed journal Nutrients. This innovative study protocol in human validated the bioavailability of 20 metabolites of interest and demonstrated a dual hepatic mode of action of TOTUM•070, on de novo cholesterol synthesis and storage of cholesterol by liver cells. These positive and very promising results were selected and presented at the American Heart Association congress in November 2022.
With an Impact Factor of 6.7, Nutrients is an international journal of influence in the field of human nutrition.
See post 